Alembic Pharmaceuticals has informed the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Desipramine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg. In this regard, the company has enclosed a press release titled ‘Alembic Pharmaceuticals announces USFDA Final Approval for Desipramine Hydrochloride Tablets USP, 10 mg. 25 mg. 50 mg, 75 mg, 100 mg, and 150 mg’.
The above information is a part of company’s filings submitted to BSE.
